Kiniksa Pharmaceuticals Statistics
Share Statistics
Kiniksa Pharmaceuticals has 72.97M
shares outstanding. The number of shares has increased by 2.4%
in one year.
| Shares Outstanding | 72.97M |
| Shares Change (YoY) | 2.4% |
| Shares Change (QoQ) | 0.61% |
| Owned by Institutions (%) | 54.61% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 1,918 |
| FTD / Avg. Volume | 0.3% |
Short Selling Information
The latest short interest is 3.31M, so 4.53% of the outstanding
shares have been sold short.
| Short Interest | 3.31M |
| Short % of Shares Out | 4.53% |
| Short % of Float | 8.49% |
| Short Ratio (days to cover) | 6.63 |
Valuation Ratios
The PE ratio is -32.71 and the forward
PE ratio is 21.04.
Kiniksa Pharmaceuticals's PEG ratio is
0.08.
| PE Ratio | -32.71 |
| Forward PE | 21.04 |
| PS Ratio | 3.34 |
| Forward PS | 1.8 |
| PB Ratio | 3.22 |
| P/FCF Ratio | 55.59 |
| PEG Ratio | 0.08 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for Kiniksa Pharmaceuticals.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.3,
with a Debt / Equity ratio of 0.02.
| Current Ratio | 3.3 |
| Quick Ratio | 3.04 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | -0.22 |
| Debt / FCF | 0.39 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $1,343,615.87 |
| Profits Per Employee | $-137,120.63 |
| Employee Count | 315 |
| Asset Turnover | 0.73 |
| Inventory Turnover | 2.31 |
Taxes
| Income Tax | 7.04M |
| Effective Tax Rate | -19.48% |
Stock Price Statistics
The stock price has increased by 41.55% in the
last 52 weeks. The beta is 0.07, so Kiniksa Pharmaceuticals's
price volatility has been higher than the market average.
| Beta | 0.07 |
| 52-Week Price Change | 41.55% |
| 50-Day Moving Average | 23.85 |
| 200-Day Moving Average | 22.85 |
| Relative Strength Index (RSI) | 65.26 |
| Average Volume (20 Days) | 638,993 |
Income Statement
In the last 12 months, Kiniksa Pharmaceuticals had revenue of 423.24M
and earned -43.19M
in profits. Earnings per share was -0.6.
| Revenue | 423.24M |
| Gross Profit | 362.33M |
| Operating Income | -45.62M |
| Net Income | -43.19M |
| EBITDA | -45.62M |
| EBIT | -45.62M |
| Earnings Per Share (EPS) | -0.6 |
Full Income StatementBalance Sheet
The company has 183.58M in cash and 9.86M in
debt, giving a net cash position of 173.73M.
| Cash & Cash Equivalents | 183.58M |
| Total Debt | 9.86M |
| Net Cash | 173.73M |
| Retained Earnings | -521.14M |
| Total Assets | 599.33M |
| Working Capital | 258.64M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was 25.69M
and capital expenditures -277K, giving a free cash flow of 25.41M.
| Operating Cash Flow | 25.69M |
| Capital Expenditures | -277K |
| Free Cash Flow | 25.41M |
| FCF Per Share | 0.36 |
Full Cash Flow StatementMargins
Gross margin is 85.61%, with operating and profit margins of -10.78% and -10.21%.
| Gross Margin | 85.61% |
| Operating Margin | -10.78% |
| Pretax Margin | -8.54% |
| Profit Margin | -10.21% |
| EBITDA Margin | -10.78% |
| EBIT Margin | -10.78% |
| FCF Margin | 6% |
